• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Milestone Pharmaceuticals Inc.

    3/13/25 7:28:11 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MIST alert in real time by email
    S-8 1 tm258922d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 13, 2025

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Milestone Pharmaceuticals Inc.

    (Exact name of registrant as specified in its charter)

     

    Québec Not applicable
    (State or other jurisdiction of
    incorporation or organization)
    (IRS employer
    identification number)
       
    1111 Dr. Frederik-Philips Boulevard, Suite 420  
    Montréal, Québec CA H4M 2X6
    (Address of Principal Executive Offices) (Zip Code)

     

    2019 Equity Incentive Plan

    2019 Employee Share Purchase Plan

    (Full titles of the plans)

     

    Joseph Oliveto

    Chief Executive Officer

    Milestone Pharmaceuticals USA Inc.

    6210 Ardrey Kell Road

    Suite 650

    Charlotte, NC 28277

    (514) 336-0444

    (Name, address, including zip code and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Ryan S. Sansom

    Peter Byrne

    Cooley LLP

    500 Boylston Street, 14th Floor

    Boston, MA 02116

    (617) 937-2300

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    PART I

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Milestone Pharmaceuticals Inc. (the “Registrant”) for the purpose of registering (i) an additional 2,134,159 common shares issuable pursuant to the Milestone Pharmaceuticals Inc. 2019 Equity Incentive Plan (the “2019 EIP”) and (ii) an additional 487,837 common shares issuable pursuant to the Milestone Pharmaceuticals Inc. 2019 Employee Share Purchase Plan (the “2019 ESPP”), pursuant to the provisions of each plan which provide for annual automatic increases in the number of shares of common stock reserved for issuance under each respective plan.

     

    In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Securities and Exchange Commission (“SEC”) are incorporated by reference into this registration statement (other than information furnished under Item 2.02 or Item 7.01 of Form 8-K or other portions of documents filed with the SEC which are furnished, but not filed, pursuant to applicable rules promulgated by the SEC):

     

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed on March 13, 2025 (the “Annual Report”);
       
    (b) The description of Common Stock which is contained in a registration statement on Form 8-A filed on May 6, 2019 (File No. 001-38899) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.
       
    (c) The Registrant’s Registration Statement on Form S-8, previously filed with the Commission on May 9, 2019 (File No. 333-231347), March 6, 2020 (File No. 333-236971), March 29, 2021 (File No. 333-254838), March 24, 2022 (File No. 333-263807), April 28, 2023 (File No. 333-271522) and November 12, 2024 (File No. 333-283160); and
       
    (d) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities

     

    See the description of the Registrant’s registered securities contained in Exhibit 4.5 to the Annual Report.

     

     

     

     

    Item 8. Exhibits.

     

    The exhibits to this Registration Statement are listed below:

     

    Exhibit    
    Number   Exhibit Description
         
    4.1   Amended Articles of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on May 15, 2019).
         
    4.2   Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on May 15, 2019).
         
    4.3   Form of Common Share Certificate (incorporated herein by reference to Exhibit 4.1 to Amendment No. 1 to the Registrant’s Registration Statement on Form S 1 (File No. 333-230846), filed with the SEC on April 29, 2019).
         
    4.4   2019 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Quarterly Report (File No. 001-38899), filed with the SEC on November 10, 2022)
         
    4.5   Form of U.S. Stock Option Grant Notice and Stock Option Agreement under the 2019 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.4 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-230846), filed with the SEC on April 29, 2019).
         
    4.6   Form of U.S. Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2019 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.5 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-230846), filed with the SEC on April 29, 2019).
         
    4.7   Form of Canadian Stock Option Grant Notice and Option Agreement under the 2019 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.6 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-230846), filed with the SEC on April 29, 2019).
         
    4.8   Form of Canadian Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2019 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.7 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-230846), filed with the SEC on April 29, 2019).
         
    4.9   2019 Employee Share Purchase Plan (incorporated herein by reference to Exhibit 4.13 to the Registrant’s Registration Statement on Form S-8 (File No. 333-231347), filed with the SEC on May 9, 2019).
         
    5.1*   Opinion of Osler, Hoskin & Harcourt LLP.
         
    23.1*   Consent of Independent Registered Public Accounting Firm.
         
    23.2*   Consent of Osler, Hoskin & Harcourt LLP. (included in Exhibit 5.1).
         
    24.1*   Power of Attorney (included on the signature page to this Registration Statement).
         
    107*   Filing Fee Table

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Montréal, Province of Québec, Canada on March 13, 2025.

     

    Milestone Pharmaceuticals Inc.  
       
    By: /s/ Joseph Oliveto  
      Joseph Oliveto  
      President and Chief Executive Officer  

     

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joseph Oliveto and Amit Hasija, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Joseph Oliveto   President, Chief Executive Officer and Director    
    Joseph Oliveto   (Principal Executive Officer)   March 13, 2025
             
    /s/ Amit Hasija   Chief Financial Officer    
    Amit Hasija   (Principal Financial and Accounting Officer)   March 13, 2025
             
    /s/ Stuart Duty        
    Stuart Duty   Director   March 13, 2025
             
    /s/ Seth Fischer        
    Seth Fischer   Director   March 13, 2025
             
    /s/ Lisa Giles        
    Lisa Giles   Director   March 13, 2025
             
    /s/ Joseph Papa        
    Joseph Papa   Director   March 13, 2025
             
    /s/ Andrew Saik        
    Andrew Saik   Director   March 13, 2025
             
    /s/ Michael Tomsicek        
    Michael Tomsicek   Director   March 13, 2025
             
    /s/ Robert Wills        
    Robert Wills   Director   March 13, 2025

     

     

     

     

    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT

     

    Pursuant to the Securities Act, the undersigned, the duly authorized representative in the United States of Milestone Pharmaceuticals Inc. has signed this registration statement or amendment thereto on March 13, 2025.

     

    MILESTONE PHARMACEUTICALS USA, INC.
       
    By: /s/ Joseph Oliveto  
      Joseph Oliveto  
      President and Chief Executive Officer  

     

     

     

    Get the next $MIST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MIST

    DatePrice TargetRatingAnalyst
    8/22/2024$9.00Buy
    Rodman & Renshaw
    6/20/2023$8.00 → $4.00Buy → Hold
    Jefferies
    4/22/2022$8.00 → $10.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $MIST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Milestone Pharmaceuticals Inc.

      SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

      10/29/24 4:30:20 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Milestone Pharmaceuticals Inc.

      SC 13D/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

      7/16/24 6:06:24 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Milestone Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

      2/14/24 8:56:08 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIST
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Milestone Pharmaceuticals Inc.

      DEFA14A - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

      4/30/25 5:02:29 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Milestone Pharmaceuticals Inc.

      DEF 14A - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

      4/30/25 5:01:18 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Milestone Pharmaceuticals Inc.

      SCHEDULE 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

      4/30/25 4:00:20 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Nelson Jeffrey Edward

      4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

      1/29/25 4:15:17 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Muller Lorenz

      4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

      1/29/25 4:15:15 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO & EVP of Corp. Development Hasija Amit

      4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

      1/29/25 4:15:15 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Issues Complete Response Letter for Etripamil for PSVT

      CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024  MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, a prescription medication in development for the conversion of acute episodes of PSVT to sinus rhythm in adults. The FDA did not raise any concerns regarding etripamil clinical safety or efficacy data and highlighted two key Chemistry, Manufact

      3/28/25 7:00:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

      MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a moderated poster presentation at the American College of Cardiology annual meeting (ACC25), to be held March 29th to 31st, 2025 in Chicago, Illinois. "This presentation highlights the potential ability of etripamil to successfully convert multiple episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to restore normal sinus rhythm. Further, the data showed that conversion of earlier episodes was predictive of conversion

      3/20/25 8:00:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Milestone Pharmaceuticals with a new price target

      Rodman & Renshaw initiated coverage of Milestone Pharmaceuticals with a rating of Buy and set a new price target of $9.00

      8/22/24 7:32:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals downgraded by Jefferies with a new price target

      Jefferies downgraded Milestone Pharmaceuticals from Buy to Hold and set a new price target of $4.00 from $8.00 previously

      6/20/23 7:40:01 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Milestone Pharmaceuticals from Neutral to Overweight and set a new price target of $10.00 from $8.00 previously

      4/22/22 7:40:09 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIST
    Financials

    Live finance-specific insights

    See more
    • Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

      New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, for patients with PSVT Positive Phase 2 data evaluating etripamil in AFib-RVR were a Featured Science Presentation at 2023 AHA Scientific Sessions; Phase 3 program expected to begin enrollment in mid-2024Company to host Investor and Analyst Webcast to review data from ReVeRA Phase 2 study of etripamil in atrial fibrillation with rapid ventricular rate today at 8:00 a.m. ETMONTREAL and CHARLOTTE, N.C., Nov. 13, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today reported financial results for the third quarter ended Septem

      11/13/23 6:57:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate

      -  Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes -  Data featured in an oral session at the Heart Rhythm 2023 Annual Meeting -  Company to host virtual KOL conference call and webcast to discuss etripamil development for the treatment of AFib-RVR today at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., May 22, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced promising data from an ad hoc analysis of a subset of patients experien

      5/22/23 7:00:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate

      -  Cardiac Electrophysiology Key Opinions Leaders to include Paul Dorian, MD, and Jonathan Piccini, MD -  Conference call and webcast on Monday, May 22, 2023 at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., May 8, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Monday, May 22, 2023 at 8:00 a.m. ET. The event will focus on etripamil, the Company's lead investigational product, for the potential treatment of patients with atrial fibrillation (AFib) and rapid ventricular rate (A

      5/8/23 7:00:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIST
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

      MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

      9/4/24 8:00:00 AM ET
      $CADL
      $EBS
      $MIST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update

      -       RAPID topline data readout remains on track for mid-second half 2022 -       Results from NODE-302 study highlights etripamil safety and reduced need for ED interventions MONTREAL and CHARLOTTE, N.C., May 12, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2022, and provided a clinical and corporate update. "The beginning of 2022 has been a productive time for Milestone, marked by continued progress advancing our lead Phase 3 program, etripamil, for patients with PSVT," said Josep

      5/12/22 7:15:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care